Report cover image

Non-Small Cell Lung Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Publisher GlobalData
Published Nov 17, 2022
Length 164 Pages
SKU # GBDT17563151

Description

Non-Small Cell Lung Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in NSCLC therapeutics.

Synopsis
  • In 2022, there will be more than 1.5 million diagnosed prevalent cases of NSCLC across 16 pharmaceutical markets.
  • There are 46 marketed innovator drugs for the treatment of NSCLC, mostly protein/peptide inhibitors and receptor antagonists.
  • R&D activity in NSCLC is high globally, with 24 products in pre-registration and 101 products in Phase III development.
  • Commercial sponsors dominate clinical trial development in NSCLC, with Canada, UK and the US emerging as the key countries for conducting Phase III trials in NSCLC.
  • During the past 12 months, 28 strategic alliances involving NSCLC assets were successfully completed.
  • Key players in the marketed drugs space for NSCLC are more inclined towards life cycle management, while emerging players are focused on launching novel investigational drugs for the treatment on a global scale.
Scope

GlobalData’s NSCLC: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Retail or Manufacturer Price of Products
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the NSCLC market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NSCLC market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

164 Pages
  • Report scope
  • Abbreviations
  • Key Findings
  • Disease Overview
    • Epidemiology Overview: Diagnosed Prevalent Cases of NSCLC in 2022 and 2027
  • Treatment Guidelines
    • Marketed Drugs - Leading Marketed Drugs in NSCLC
    • Marketed Drugs - Overview by Mechanism of Action
    • Marketed Drugs - Overview by Route of Administration
    • Marketed Drugs - Overview by Molecule Type
    • Marketed Drug Profile: Merck's Keytruda
    • Marketed Drug Profile: Bristol Myers Squibb/Ono Pharma's Opdivo/Opdyta
    • Marketed Drug Profile: AstraZeneca's Tagrisso
    • Marketed Drug Profile: Roche's Tecentriq
    • Marketed Drug Profile: Roche's Avastin
    • Marketed Drug Profile: AstraZeneca's Imfinzi
    • Marketed Drug Profile: Novartis's Mekinist
    • Marketed Drug Profile: Bristol Myers Squibb's Yervoy
    • Marketed Drug Profile: Novartis's Tafinlar + Mekinist
    • Marketed Drug Profile: Roche's Alecensa
    • Marketed Drug Profile: Eli Lilly's Cyramza
    • Marketed Drug Profile: Pfizer's Xalkori
    • Marketed Drug Profile: Regeneron's Libtayo
    • Marketed Drug Profile: Merck Serono's Tepmetko
    • Marketed Drug Profile: Pfizer's Lorbrena/Lorviqua/Lorlak
    • Marketed Drug Profile: Takeda's Alunbrig
    • Marketed Drug Profile: Loxo's Retevmo
    • Marketed Drug Profile: Novartis's Tabrecta
    • Marketed Drug Profile: Amgen's Lumakras/Lumykras
    • Marketed Drug Profile: Blueprint's Gavreto
    • Marketed Drug Profile: Novartis's Zykadia
    • Marketed Drug Profile: Roche's Rozlytrek
    • Marketed Drug Profile : Novartis's Tafinlar
    • Marketed Drug Profile: Janssen's Rybrevant
    • Marketed Drug Profile: Pfizer's Vizimpro
    • Marketed Drug Profile: Takeda's Exkivit; Exkivity
    • Marketed Drug Profile: Astellas/Roche's Tarceva
    • Marketed Drug Profile: Boehringer's Gilotrif/Giotrif/Xovoltib
    • Marketed Drug Profile: Boehringer's Vargatef/Cyendiv/Ofev
    • Marketed Drug Profile: AstraZeneca's Gefitinib/Iressa
    • Marketed Drug Profile: Eli Lilly's Portrazza
    • Marketed Drugs - Manufacturer Price for Intravenous Formulations in NSCLC
    • Marketed Drugs - Manufacturer Price for Oral Formulations in NSCLC
    • Marketed Drugs - Manufacturer Price ($/mg)
    • Marketed Drugs - Time to Pricing and Reimbursement for Pembrolizumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Nivolumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Atezolizumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Durvalumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Ipilumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Alectinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Ramucirumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Cemiplimab
    • Marketed Drugs - Time to Pricing and Reimbursement for Amivantamab
    • Marketed Drugs - Time to Pricing and Reimbursement for Bevacizumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Ceritinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Dacomitinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Nintedanib
    • Marketed Drugs - Time to Pricing and Reimbursement for Necitumumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Trametinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Osimertinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Lorlatinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Brigatinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Capmatinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Selpercatinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Sotorasib
    • Marketed Drugs - Time to Pricing and Reimbursement for Entrectinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Pralsetinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Dabrafenib
    • Marketed Drugs - Time to Pricing and Reimbursement for Afatinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Erlotinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Tepotinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Crizotinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Gefitinib
    • Pipeline Drugs Overview - Pre-registration and Phase III Pipeline Drugs in NSCLC
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Drug-Specific PTSR and LoA in NSCLC
    • Pipeline Drugs - PTSRs and LoAs in Oncology and in NSCLC
    • Clinical Trials in NSCLC - Historical Overview
    • Clinical Trials in NSCLC - Overview by Phase
    • Clinical Trials in NSCLC - Overview by Status
    • Clinical Trials in NSCLC - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in NSCLC - Trials with a Virtual Component
    • Clinical Trials in NSCLC - Geographic Overview
    • Clinical Trials in NSCLC - Single-Country and Multinational Trials by Region
    • Clinical Trials in NSCLC - Top 20 Sponsors with Breakdown by Phase
    • Clinical Trials in NSCLC - Top 20 Sponsors with Breakdown by Status
    • Clinical Trials in NSCLC - Overview by Endpoint Status
    • Clinical Trials in NSCLC - Overview by Race and Ethnicity
    • Clinical Trials in NSCLC - Enrollment Data
    • Clinical Trials in NSCLC - Overview of Sites by Geography
    • Clinical Trials in NSCLC - Top 20 Countries for Trial Sites
    • Clinical Trials in NSCLC - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for NSCLC
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in NSCLC by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in NSCLC
    • Commercial Assessment - Key Market Players in NSCLC
    • Future Market Catalysts - Upcoming Market Catalysts in NSCLC
    • Methodology
    • Methodology - Sales Forecasts
    • Methodology - Pricing and Reimbursement
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis
    • About the Authors
    • Contact Us - A Global Network of Offices

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us